Ownership Submission
FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Kumar Ramesh
2. Date of Event Requiring Statement (Month/Day/Year)
07/24/2013
3. Issuer Name and Ticker or Trading Symbol
Onconova Therapeutics, Inc. [ONTX]
(Last)
(First)
(Middle)
C/O ONCONOVA THERAPEUTICS, INC., 375 PHEASANT RUN
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
President and CEO
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

NEWTOWN, PA 18940
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 92,911
D
 
Common Stock 150,037
I
By the Ramesh Kumar 2012 Trust (12)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Series A Convertible Preferred Stock   (1)   (1) Common Stock 4,667 $ (1) D  
Series B Convertible Preferred Stock   (2)   (2) Common Stock 20,645 $ (2) D  
Series C Convertible Preferred Stock   (3)   (3) Common Stock 983 $ (3) D  
Series D Convertible Preferred Stock   (4)   (4) Common Stock 2,209 $ (4) D  
Series E Convertible Preferred Stock   (5)   (5) Common Stock 1,084 $ (5) D  
Series F Convertible Preferred Stock   (6)   (6) Common Stock 500 $ (6) D  
Series G Convertible Preferred Stock   (7)   (7) Common Stock 765 $ (7) D  
Series H Convertible Preferred Stock   (8)   (8) Common Stock 500 $ (8) D  
Series I Convertible Preferred Stock   (9)   (9) Common Stock 100 $ (9) D  
Stock Option (right to purchase) 12/31/2005 01/01/2016 Common Stock 5,256 $ 2.67 D  
Stock Option (right to purchase) 03/31/2011 04/01/2017 Common Stock 105,026 $ 6 D  
Stock Option (right to purchase) 03/17/2010 03/17/2020 Common Stock 18,754 $ 5.76 D  
Stock Option (right to purchase)   (10) 03/17/2020 Common Stock 75,018 $ 5.76 D  
Stock Option (right to purchase) 12/10/2010 12/10/2020 Common Stock 52,513 $ 6.13 D  
Stock Option (right to purchase) 12/05/2011 12/05/2021 Common Stock 10,335 $ 6.13 D  
Stock Option (right to purchase) 12/18/2012 12/19/2022 Common Stock 93,773 $ 13.28 D  
Stock Option (right to purchase)   (11) 12/19/2022 Common Stock 93,773 $ 13.28 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Kumar Ramesh
C/O ONCONOVA THERAPEUTICS, INC.
375 PHEASANT RUN
NEWTOWN, PA 18940
  X     President and CEO  

Signatures

/s/ Ramesh Kumar 07/24/2013
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The convertible preferred stock is convertible at any time, at the holder's election, and is automatically convertible immediately prior to the consummation of the Issuer's initial public offering on a 0.80-for-1 basis and has no expiration date.
(2) The convertible preferred stock is convertible at any time, at the holder's election, and is automatically convertible immediately prior to the consummation of the Issuer's initial public offering on a 0.85-for-1 basis and has no expiration date.
(3) The convertible preferred stock is convertible at any time, at the holder's election, and is automatically convertible immediately prior to the consummation of the Issuer's initial public offering on a 0.75-for-1 basis and has no expiration date.
(4) The convertible preferred stock is convertible at any time, at the holder's election, and is automatically convertible immediately prior to the consummation of the Issuer's initial public offering on a 0.75-for-1 basis and has no expiration date.
(5) The convertible preferred stock is convertible at any time, at the holder's election, and is automatically convertible immediately prior to the consummation of the Issuer's initial public offering on a 0.75-for-1 basis and has no expiration date.
(6) The convertible preferred stock is convertible at any time, at the holder's election, and is automatically convertible immediately prior to the consummation of the Issuer's initial public offering on a 0.77-for-1 basis and has no expiration date.
(7) The convertible preferred stock is convertible at any time, at the holder's election, and is automatically convertible immediately prior to the consummation of the Issuer's initial public offering on a 0.75-for-1 basis and has no expiration date
(8) The convertible preferred stock is convertible at any time, at the holder's election, and is automatically convertible immediately prior to the consummation of the Issuer's initial public offering on a 0.75-for-1 basis and has no expiration date.
(9) The convertible preferred stock is convertible at any time, at the holder's election, and is automatically convertible immediately prior to the consummation of the Issuer's initial public offering on a 0.75-for-1 basis and has no expiration date.
(10) This option, representing a right to purchase a total of 75,018 shares of Common Stock, is immediately exercisable and vests over 4 years from March 17, 2010, with 25% vesting on March 17, 2011 and 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date.
(11) This option, representing a right to purchase a total of 93,773 shares of Common Stock, is immediately exercisable and vests over 4 years from December 18, 2012, with 25% vesting on December 18, 2013 and 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date
(12) The reporting person is the trustee of the trust.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.